Shen, M., Hao, Y., Han, X., Wang, B., Li, L., Chen, T., Chen, S., Zou, L., Huang, J., Wang, W., Liu, S., Han, X., Jin, A.

Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumors

18 de July de 2025 by Shen, M., Hao, Y., Han, X., Wang, B., Li, L., Chen, T., Chen, S., Zou, L., Huang, J., Wang, W., Liu, S., Han, X., Jin, A.

Background
Public neoantigens, including KRAS, TP53, and PIK3CA mutations, which are shared across various tumor types, have demonstrated significant immunogenicity and offer great promise for cancer immunotherapy. Clinical trials targeting these publ…